Corpus overview


Overview

MeSH Disease

Human Phenotype

Pneumonia (48)

Fever (13)

Cough (7)

Fatigue (5)

Dyspnea (4)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 48
    records per page




    Clinical evolution of COVID-19 during pregnancy at different altitudes: a population-based study

    Authors: Juan Alonso Leon-Abarca; Maria Teresa Pena-Gallardo; Jorge Soliz; Roberto Alfonso Accinelli; Catherine Aiken

    doi:10.1101/2020.09.14.20193177 Date: 2020-09-18 Source: medRxiv

    Background: The impact of influenza and various types of coronaviruses ( SARS-CoV and MERS-CoV MESHD) on pregnancy has been reported. However, the current pandemic caused by SARS-CoV-2 continues to reveal important data for understanding its behavior in pregnant women. Methods: We analyzed the records of 326,586 non-pregnant women of reproductive age TRANS and 7,444 pregnant women with no other risk factor who also had a SARS-CoV-2 RT-PCR result to estimate adjusted prevalence SERO (aP) and adjusted prevalence SERO ratios (aPR) of COVID-19 and its requirement of hospitalization, intubation, ICU admission and case-fatality rates. Adjustment was done through Poisson regressions for age TRANS and altitude of residence and birth. Generalized binomial models were used to generate probability plots to display how each outcome varied across ages TRANS and altitudes. Results: Pregnancy was independently associated with a 15% higher probability of COVID-19 (aPR: 1.15), a 116% higher probability of its following admission (aPR: 2.169) and a 127% higher probability of ICU admission (aPR: 2.275). Also, pregnancy was associated with 84.2% higher probability of developing pneumonia HP pneumonia MESHD (aPR: 1.842) and a 163% higher probability of its following admission (aPR: 2.639). There were no significant differences in COVID-19 case-fatality rates between pregnant and non pregnant women (1.178, 95% CI: 0.68-1.67). Conclusion: Pregnancy was associated with a higher probability of COVID-19, developing of pneumonia HP pneumonia MESHD, hospitalization, and ICU admission. Our results also suggest that the risk of COVID-19 and its related outcomes, except for intubation, decrease with altitude. Keywords: COVID-19, SARS-CoV-2, pregnancy, reproductive age TRANS, altitude

    Pulmonary fibrosis HP Pulmonary fibrosis MESHD and its related factors in discharged patients with new coronavirus pneumonia MESHD pneumonia HP: A cohort study of 90-150 days follow-up after onset

    Authors: Xiaohe Li; Chenguang Shen; Lifei Wang; Sumit Majumder; Die Zhang; M. Jamal Deen; Yanjie Li; Ling Qing; Ying Zhang; Chuming Chen; Rongrong Zou; Jianfeng Lan; Ling Huang; Cheng Peng; Lijiao Zeng; Yanhua Liang; Mengli Cao; Yang Yang; Minghui Yang; Guoyu Tan; Shenghong Tang; Lei Liu; Jing Yuan; Yingxia Liu

    doi:10.21203/rs.3.rs-79977/v1 Date: 2020-09-18 Source: ResearchSquare

    Background: Thousands of the Coronavirus Disease MESHD 2019 (COVID-19) patients have been discharged from hospitals, long-term follow-up studies are required to evaluate the prevalence SERO of post-COVID-19 fibrosis MESHD.Methods: This study involves 462 laboratory confirmed patients with COVID-19 who were admitted to Shenzhen Third People’s Hospital from January 11, 2020 to April 26, 2020. A total of 457 patients underwent thin-section chest CT scans during the hospitalization or after discharge to identify the pulmonary lesion MESHD. A total of 289 patients were followed up from 90 days to 150 days after the onset of the disease.Results:  Parenchymal bands, irregular interfaces, meshwork and traction bronchiectasis HP were the most common CT features in all COVID-19 patients. 86.87%, 74.40%, 79.56%, 68.12% and 62.03% patients developed with pulmonary fibrosis HP pulmonary fibrosis MESHD and 4.53%, 19.61%, 18.02%, 38.30% and 48.98% patients reversed pulmonary fibrosis HP pulmonary fibrosis MESHD during the 0-30, 31-60, 61-90, 91-120 and >120 days after onset, respectively. It was observed that Age TRANS, BMI, Fever HP Fever MESHD, and Highest PCT were predictive factors for sustaining fibrosis MESHD even after 90 days from onset. A predictive model of the persistence with pulmonary fibrosis HP pulmonary fibrosis MESHD was developed based-on the Logistic Regression method with an accuracy, PPV, NPV, Sensitivity SERO and Specificity of the model of 76%, 71%, 79%, 67%, and 82%, respectively. Only a fraction of COVID-19 patients suffered with abnormal lung function MESHD after 90 days from onset, and the ratio of abnormal lung function did not differ on a statistically significant level between the fibrotic and non-fibrotic groups.Conclusions: Long-term pulmonary fibrosis HP pulmonary fibrosis MESHD was more likely to develop in patients with older age TRANS, high BMI, severe/critical condition, fever HP fever MESHD, long time to turn the viral RNA negative, pre-existing disease and delay to admission. Fibrosis MESHD developed in COVID-19 patients could be reversed in about a half of the patients after 120 days from onset. The pulmonary function of most of COVID-19 patients with pulmonary fibrosis HP pulmonary fibrosis MESHD could turn to normal condition after three months from onset. An effective prediction model with an average Area Under the Curve (AUC) of 0.84 was established to predict the persistence of pulmonary fibrosis HP pulmonary fibrosis MESHD in COVID-19 patients for early diagnosis.

    The impact of COVID-19 in diabetic kidney disease MESHD kidney disease and chronic HP chronic kidney disease MESHD: A population-based study

    Authors: Juan Alonso Leon-Abarca; Roha Saeed Memon; Bahar Rehan; Maimoona Iftikhar; Antara Chatterjee; Andrés Gonzalez-Guerra; Emilio Camafeita; Mariya Lytvyn; María Isabel Guillén; David Sanz-Rosa; Daniel Martín-Pérez; Cristina Sanchez-Ramos; Ricardo Garcia; Juan Antonio Bernal; Sijia Tao; Tristan R Horton; Elizabeth N Beagle; Ernestine A Mahar; Michelle YH Lee; Joyce Cohen; Sherrie Jean; Jennifer S Wood; Fawn Connor-Stroud; Rachelle L Stammen; Olivia M Delmas; Shelly Wang; Kimberly A Cooney; Michael N Sayegh; Lanfang Wang; Daniela Weiskopf; Peter D Filev; Jesse Waggoner; Anne Piantadosi; Sudhir P Kasturi; Hilmi Al-Shakhshir; Susan P Ribeiro; Rafick P Sekaly; Rebecca D Levit; Jacob D Estes; Thomas H Vanderford; Raymond F Schinazi; Steven E Bosinger; Mirko Paiardini

    doi:10.1101/2020.09.12.20193235 Date: 2020-09-16 Source: medRxiv

    Background: The spectrum of pre-existing renal disease MESHD is known as a risk factor for severe COVID-19 outcomes. However, little is known about the impact of COVID-19 on patients with diabetic nephropathy MESHD nephropathy HP in comparison to patients with chronic kidney disease HP chronic kidney disease MESHD. Methods: We used the Mexican Open Registry of COVID-19 patients 11 to analyze anonymized records of those who had symptoms related to COVID-19 to analyze the rates of SARS-CoV-2 infection MESHD, development of COVID-19 pneumonia HP pneumonia MESHD, admission, intubation, Intensive Care Unit admission and mortality. Robust Poisson regression was used to relate sex and age TRANS to each of the six outcomes and find adjusted prevalences SERO and adjusted prevalence SERO ratios. Also, binomial regression models were performed for those outcomes that had significant results to generate probability plots to perform a fine analysis of the results obtained along age TRANS as a continuous variable. Results: The adjusted prevalence SERO analysis revealed that that there was a a 87.9% excess probability of developing COVID-19 pneumonia HP pneumonia MESHD in patients with diabetic nephropathy MESHD nephropathy HP, a 5% excess probability of being admitted, a 101.7% excess probability of intubation and a 20.8% excess probability of a fatal outcome due to COVID-19 pneumonia HP pneumonia MESHD in comparison to CKD patients (p<0.01). Conclusions: Patients with diabetic nephropathy MESHD nephropathy HP had nearly a twofold rate of COVID-19 pneumonia HP pneumonia MESHD, a higher probability of admission, a twofold probability of intubation and a higher chance of death once admitted compared to patients with chronic kidney disease HP chronic kidney disease MESHD alone. Also, both diseases had higher COVID-19 pneumonia HP pneumonia MESHD rates, intubation rates and case-fatality rates compared to the overall population. Keywords: COVID-19, SARS-CoV-2, Chronic Kidney Disease MESHD Chronic Kidney Disease HP, diabetic nephropathy MESHD nephropathy HP

    Characteristics and Prognosis of COVID-19 in Patients with COPD MESHD

    Authors: Desirée Graziani; Joan B Soriano; Carlos Del Rio-Bermudez; Diego Morena; Teresa Díaz; María Castillo; Miguel Alonso; Julio Ancochea; José Luis Izquierdo

    id:10.20944/preprints202009.0242.v1 Date: 2020-09-11 Source: Preprints.org

    Patients with COPD MESHD have a higher prevalence SERO of coronary ischemia MESHD and other factors that put them at risk for COVID-19-related complications. We aimed to explore the impact of COVID-19 in a large population-based sample of patients with COPD MESHD in Castilla-La Mancha MESHD, Spain. We analyzed clinical data in electronic health records from January 1st to May 10th, 2020 by using Natural Language Processing through the SAVANA Manager® clinical platform. Out of 31,633 COPD MESHD patients, 793 had a diagnosis of COVID-19. The proportion of patients with COVID-19 in the COPD population (2,51%; CI95% 2,33 – 2,68) was significantly higher than in the general population aged TRANS > 40 years (1,16%; 95%CI 1,14 – 1,18); P < .001. Compared with COPD-free individuals, COPD MESHD patients with COVID-19 showed significantly poorer disease prognosis, as evaluated by hospitalizations (31,1 % vs 39,8%: OR 1,57; 95%CI 1,14 – 1,18) and mortality (3,4% vs 9,3%: OR 2,93; 95%CI 2,27 – 3,79). Patients with COPD MESHD and COVID-19 were significantly older (75 vs. 66 years), predominantly male TRANS (83% vs 17%), smoked more frequently, and had more comorbidities than their non-COPD counterparts. Pneumonia HP was the most common diagnosis among COPD MESHD patients hospitalized due to COVID-19 (59%); 19% of patients showed pulmonary infiltrates HP suggestive of pneumonia HP pneumonia MESHD and heart failure MESHD. Mortality in COPD MESHD patients with COVID-19 was associated with older age TRANS and prevalence SERO of heart failure MESHD (P<0.05). COPD MESHD patients with COVID-19 showed higher rates of hospitalization and mortality, mainly associated with pneumonia HP pneumonia MESHD. This clinical profile is different from exacerbations caused by other respiratory viruses in the winter season.

    Risk Factors For COVID-19 Positivity in Hospitalized Patients in A Low Prevalence SERO Setting

    Authors: Iris Zohar; Orna Schwartz; Debby Ben David; Margarita Mashavi; Mohamad Aboulil; Orit Yossepowitch; Shirley Shapiro Ben David; ‪Yasmin Maor‬‏

    doi:10.21203/rs.3.rs-72761/v1 Date: 2020-09-05 Source: ResearchSquare

    Background: Identifying hospitalized patients with Coronavirus disease MESHD 2019 (COVID-19) in a low prevalence SERO setting is challenging.  We aimed to identify differences between COVID-19 positive and negative patients. Methods: Hospitalized patients with respiratory illness MESHD, or fever HP fever MESHD, were isolated in the emergency room and tested for COVID-19. Patients with a negative PCR and low probability for COVID-19 were taken out of isolation. Patients with a higher probability for COVID-19 remained in isolation during hospitalization and were retested after 48 hours. Risk factors for COVID-19 were assessed using logistic regression. Results: 254 patients were included, 37 COVID-19-positive (14.6%) and 217 COVID-19-negative (85.4%). Median age TRANS was 76 years, 52% were males TRANS. In a multivariate regression model, variables significantly associated with COVID-19 positivity were exposure to a confirmed COVID-19 case, length of symptoms before testing, bilateral and peripheral infiltrates in chest X-ray, neutrophil count within the normal range, and elevated LDH. In an analysis including only patients with pneumonia HP pneumonia MESHD (N=78, 18 positive for COVID-19), only bilateral and peripheral infiltrates, normal neutrophil count and elevated LDH were associated with COVID-19 positivity. Conclusions: The clinical presentation of COVID-19 positive and negative patients is similar, but radiographic and laboratory features may help to identify COVID-19 positive patients and to initiate quick decisions regarding isolation.

    Seroprevalence SERO of anti- SARS-CoV-2 antibodies SERO in COVID-19 patients and healthy volunteers

    Authors: Patricia Figueiredo-Campos; Birte Blankenhaus; Catarina Mota; Andreia Gomes; Marta Serrano; Silvia Ariotti; Catarina Costa; Helena Nunes-Cabaco; Antonio M Mendes; Pedro Gaspar; Conceicao M Pereira-Santos; Fabiana Rodrigues; Jorge Condeco; Antonia M Escoval; Matilde Santos; Mario Ramirez; Jose Melo-Cristino; Pedro J Simas; Eugenia Vasconcelos; Angela Afonso; Marc Veldhoen; Matthew Harnett; Melody Eaton; Sandra Hatem; Hajra Jamal; Alara Akyatan; Alexandra Tabachnikova; Lora E. Liharska; Liam Cotter; Brian Fennessey; Akhil Vaid; Guillermo Barturen; Scott R. Tyler; Hardik Shah; Yinh-chih Wang; Shwetha Hara Sridhar; Juan Soto; Swaroop Bose; Kent Madrid; Ethan Ellis; Elyze Merzier; Konstantinos Vlachos; Nataly Fishman; Manying Tin; Melissa Smith; Hui Xie; Manishkumar Patel; Kimberly Argueta; Jocelyn Harris; Neha Karekar; Craig Batchelor; Jose Lacunza; Mahlet Yishak; Kevin Tuballes; Leisha Scott; Arvind Kumar; Suraj Jaladanki; Ryan Thompson; Evan Clark; Bojan Losic; - The Mount Sinai COVID-19 Biobank Team; Jun Zhu; Wenhui Wang; Andrew Kasarskis; Benjamin S. Glicksberg; Girish Nadkarni; Dusan Bogunovic; Cordelia Elaiho; Sandeep Gangadharan; George Ofori-Amanfo; Kasey Alesso-Carra; Kenan Onel; Karen M. Wilson; Carmen Argmann; Marta E. Alarcón-Riquelme; Thomas U. Marron; Adeeb Rahman; Seunghee Kim-Schulze; Sacha Gnjatic; Bruce D. Gelb; Miriam Merad; Robert Sebra; Eric E. Schadt; Alexander W. Charney

    doi:10.1101/2020.08.30.20184309 Date: 2020-09-02 Source: medRxiv

    SARS-CoV-2 has emerged as a novel human pathogen, causing clinical signs, from fever HP fever MESHD to pneumonia HP pneumonia MESHD - COVID-19 - but may remain mild or even asymptomatic TRANS. To understand the continuing spread of the virus, to detect those who are and were infected, and to follow the immune response longitudinally, reliable and robust assays for SARS-CoV-2 detection and immunological monitoring are needed and have been setup around the world. We quantified immunoglobulin M (IgM), IgG and IgA antibodies SERO recognizing the SARS-CoV-2 receptor-binding domain (RBD) or the Spike (S) protein over a period of five months following COVID-19 disease onset or in previously SARS-CoV-2 PCR-positive volunteers. We report the detailed setup to monitor the humoral immune response from over 300 COVID-19 hospital patients and healthcare workers, 2500 University staff and 187 post-COVID19 volunteers, and assessing titres for IgM, IgG and IgA. Anti- SARS-CoV-2 antibody SERO responses followed a classic pattern with a rapid increase within the first three weeks after symptoms. Although titres reduce from approximately four weeks, the ability to detect SARS-CoV-2 antibodies SERO remained robust for five months in a large proportion of previously virus-positive screened subjects. Our work provides detailed information for the assays used, facilitating further and longitudinal analysis of protective immunity to SARS-CoV-2. Moreover, it highlights a continued level of circulating neutralising antibodies SERO in most people with confirmed SARS-CoV-2, at least up to five months after infection.

    In Search of Patient Zero: Visual Analytics of Pathogen Transmission TRANS Pathways in Hospitals

    Authors: T. Baumgartl; M. Petzold; M. Wunderlich; M. Höhn; D. Archambault; M. Lieser; A. Dalpke; S. Scheithauer; M. Marschollek; V. M. Eichel; N. T. Mutters; HiGHmed Consortium; T. von Landesberger

    id:2008.09552v3 Date: 2020-08-21 Source: arXiv

    Pathogen outbreaks (i.e., outbreaks of bacteria and viruses) in hospitals can cause high mortality rates and increase costs for hospitals significantly. An outbreak is generally noticed when the number of infected MESHD patients rises above an endemic level or the usual prevalence SERO of a pathogen in a defined population. Reconstructing transmission TRANS pathways back to the source of an outbreak -- the patient zero or index patient -- requires the analysis of microbiological data and patient contacts. This is often manually completed by infection control experts. We present a novel visual analytics approach to support the analysis of transmission TRANS pathways, patient contacts, the progression of the outbreak, and patient timelines during hospitalization. Infection control experts applied our solution to a real outbreak of Klebsiella pneumoniae MESHD pneumoniae HP in a large German hospital. Using our system, our experts were able to scale the analysis of transmission TRANS pathways to longer time intervals (i.e., several years of data instead of days) and across a larger number of wards. Also, the system is able to reduce the analysis time from days to hours. In our final study, feedback from twenty-five experts from seven German hospitals provides evidence that our solution brings significant benefits for analyzing outbreaks. It is also applicable to COVID-19 hospital-associated transmissions TRANS.

    Abnormal Upregulation of Cardiovascular Disease MESHD Biomarker PLA2G7 Induced by Proinflammatory Macrophages in COVID-19 patients

    Authors: Yang LI; Yongzhong JIANG; Yi ZHANG; Naizhe LI; Qiangling YIN; Linlin LIU; Xin LV; Yan LIU; Aqian LI; Bin FANG; Jiajia LI; Hengping YE; Gang YANG; Xiaoxian CUI; Yang LIU; Yuanyuan QU; Chuan LI; Jiandong LI; Dexin LI; Shiwen WANG; Zhongtao GAI; Faxian ZHAN; Mifang LIANG; Scott Hensley

    doi:10.1101/2020.08.16.20175505 Date: 2020-08-18 Source: medRxiv

    BACKGROUND. Coronavirus disease MESHD 2019 (COVID-19) triggers distinct patterns of pneumonia HP pneumonia MESHD progression with multiorgan disease, calling for cell- and/or tissue-type specific host injury markers. METHODS. An integrated hypothesis-free single biomarker analysis framework was performed on nasal swabs (n=484) from patients with COVID-19 in GSE152075. The origin of candidate biomarker was assessed in single-cell RNA data (GSE145926). The candidate biomarker was validated in a cross-sectional cohort (n=564) at both nucletide and protein levels. RESULTS. Phospholipase A2 group VII (PLA2G7) was identified as a candidate biomarker in COVID-19. PLA2G7 was predominantly expressed by proinflammatory macrophages in lungs emerging with progression of COVID-19. In the validation stage, PLA2G7 was found in patients with COVID-19 and pneumonia HP pneumonia MESHD, especially in severe pneumonia HP pneumonia MESHD, rather than patients suffered mild H1N1 influenza infection MESHD. The positive rates of PLA2G7 ranging from 29.37% to 100.00% were positively correlated with not only viral loads in patients with COVID-19 but also severity of pneumonia HP pneumonia MESHD in non COVID-19 patients. Although Ct values of PLA2G7 in severe pneumonia HP pneumonia MESHD was siginificantly lower than that in moderate pneumonia HP pneumonia MESHD (P=7.2e-11), no differences were observed in moderate pneumonia HP pneumonia MESHD with COVID-19 between severe pneumonia HP pneumonia MESHD without COVID-19 (P=0.81). Serum SERO protein levels of PLA2G7, also known as lipoprotein-associated phospholipase A2 (Lp-PLA2), were further found to be elevated and beyond the upper limit of normal in patients with COVID-19, especially among the re-positive patients. CONCLUSIONS. We firstly identified and validated PLA2G7, a biomarker for cardiovascular diseases MESHD ( CVDs MESHD), was abnormally enhanced in COVID-19 patients at both nucletide and protein aspects. These findings provided indications into the prevalence SERO of cardiovascular involvements seen in COVID-19 patients. PLA2G7 could be a hallmark of COVID-19 for monitoring disease progress and therapeutic response.

    Rotational Thromboelastometry Predicts Care Level in COVID-19: A Prospective, Observational Study.

    Authors: Lou M. Almskog; Agneta Wikman; Jonas Svensson; Michael Wanecek; Matteo Bottai; Jan van der Linden; Anna Ågren

    doi:10.21203/rs.3.rs-57906/v1 Date: 2020-08-12 Source: ResearchSquare

    BackgroundHigh prevalence SERO of thrombotic MESHD events in severely ill COVID-19 patients have been reported. Pulmonary embolism HP Pulmonary embolism MESHD as well as microembolization of vital organs may in these individuals be direct causes of death MESHD. The identification of patients at high risk of developing thrombosis MESHD may lead to targeted, more effective prophylactic treatment. The aim of this study was to test whether Rotational Thromboelastometry MESHD ( ROTEM MESHD) indicates hypercoagulopathy in COVID-19 patients, and whether patients with severe disease have a more pronounced hypercoagulopathy compared with less severely ill patients. MethodsThe study was designed as a prospective observational study where COVID-19 patients over 18 years admitted to hospital were eligible for inclusion. Patients were divided into two groups depending on care level: 1) regular wards or 2) wards with specialized ventilation support. ROTEM MESHD was taken after admission and the data were compared with ROTEM MESHD in healthy controls.ResultsThe ROTEM MESHD variables Maximum Clot Firmness (EXTEM-/FIBTEM-MCF) were higher in COVID-19 patients compared with healthy controls (p<0.001) and higher in severely ill patients compared with patients at regular wards (p<0.05). Coagulation Time (EXTEM-CT) was longer and Clot Formation Time (EXTEM-CFT) shorter in COVID-19 patients compared with healthy controls. Our results suggest that hypercoagulopathy is present in hospitalized patients with mild to severe COVID-19 pneumonia HP pneumonia MESHD. ConclusionsROTEM variables were significantly different in COVID-19 patients early after admission compared with healthy controls. This pattern was more pronounced in patients with increased disease severity, suggesting that ROTEM MESHD-analysis may be useful to predict thromboembolic complications MESHD in these patients. 

    IgG seroprevalence SERO against SARS-CoV-2 in a cohort of 449 non-hospitalized, high-risk exposure individuals.

    Authors: Patricia Torres Martínez; Paula Diaque García; María Rubio Salas; Raquel Rodríguez Sánchez; Felipe García; Miguel Ángel Llamas; Paula Saz-Leal; CArlos del Fresno

    doi:10.21203/rs.3.rs-53747/v1 Date: 2020-08-04 Source: ResearchSquare

    COVID-19 pandemic caused by SARS-CoV-2 led the Spanish government to impose a national lockdown in an attempt to control the spread of the infection MESHD. Mobility restrictions but also the requirement of a medical prescription to gain access to serological testing SERO for COVID-19 were included among the measures. Under this scenario, between April 15th to June 15th, 2020, we performed a seroprevalence SERO observational study including 449 individuals that fulfill prescription requirements: manifesting COVID-19 compatible symptoms, being in contact with a COVID-19 confirmed case TRANS or belonging to essential occupations including healthcare workers, firefighters or public safety personnel such as police. Importantly, none of the participants was hospitalized. Altogether, we studied this specific, non-commonly addressed cohort for SARS-CoV-2 seroprevalence SERO, uncovering intrinsic features of great demographic interest. The overall rate of IgG seropositivity was 33.69% (95% CI: 29.27 – 38.21). This seroprevalence SERO was comparable between different occupations performed by the participants. However, contacts with confirmed cases TRANS associated positively with IgG+ results, with stronger correlation if being a household member. The number of symptoms also correlated positively with IgG+ prevalence SERO. Ageusia/anosmia, pneumonia MESHD anosmia HP, pneumonia HP and cutaneous manifestations were the top-three symptoms that most strongly associated with IgG+ seroprevalence SERO. However, while pneumonia HP pneumonia MESHD and cutaneous manifestations were barely present in our cohort, fever HP fever MESHD, ageusia/anosmia MESHD anosmia HP and asthenia HP were the most frequently symptoms described within IgG+ subjects. Therefore, our data illustrate how specific cohorts display heterogeneous characteristics that should be taken into account when identifying population seroprevalence SERO against SARS-CoV-2 and key defining symptoms for COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.